Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MY0F
|
|||
| Drug Name |
MGD013
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1/2 | [1] | |
| Hematologic tumour [ICD-11: 2B33.Y; ICD-10: D10-D36, D3A; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
MacroGenics Rockville, MD
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04212221) MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients. U.S. National Institutes of Health. | |||
| REF 2 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.